Role of the Dentist in the Control of the Alcoholic Habit in Patients with Potentially Malignant Oral Lesions
Launched by UNIVERSITY OF SANTIAGO DE COMPOSTELA · Oct 5, 2020
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether dentists can help patients with certain oral conditions, known as potentially malignant oral lesions, reduce or stop their alcohol consumption. Alcohol can increase the risk of serious health problems, including cancer, and the trial aims to see if brief interventions from dentists can make a difference for patients who drink alcohol regularly.
To participate, individuals need to be over 40 years old, diagnosed with specific chronic oral conditions, and consume alcohol daily (more than two glasses of wine or beer, or one glass of liquor). Participants will visit the dental clinic multiple times over the course of a year for evaluations related to their alcohol use, the health of their oral lesions, and their overall quality of life. If successful, this approach could be widely adopted in dental clinics to support patients in managing their alcohol habits.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with a clinical and histopathological diagnosis of oral lichen planus (OPL) and/or oral leukoplakia (LO) (in all its clinical forms) as chronic LOPMs according to the WHO 2017 classification.
- • 2. Patients over 40 years old
- • 3. Patients in follow-up, with chronic injuries, without medical and/or surgical treatment for at least 1 month
- • 4. Patients with frequent daily alcohol consumption \> 1 Standard Beverage Unit (more than two glasses of wine/beer per day or one glass of liquor/distilled drink per day)
- Exclusion Criteria:
- • 1. Participants who do not sign the informed consent.
- • 2. Patients with a score above 20 in the AUDIT.
- • 3. Patients undergoing treatment for problems with alcohol and other drugs.
- • 4. Patients with systemic pathology associated with alcohol consumption
- • 5. Pregnant patients.
- • 6. Patients undergoing active pharmacological treatment for OPL.
- • 7. Patients who have undergone surgical resection and/or CO2 laser treatment for LO in the last month.
- • 8. Patients with a history of malignant oral lesions.
About University Of Santiago De Compostela
The University of Santiago de Compostela, a prestigious institution located in Spain, is dedicated to advancing scientific research and healthcare through innovative clinical trials. With a rich history of academic excellence, the university fosters a multidisciplinary approach, bringing together experts in medicine, pharmacology, and public health to conduct rigorous studies aimed at improving patient outcomes. Committed to ethical practices and the highest standards of research integrity, the university collaborates with various stakeholders, including healthcare providers and industry partners, to translate findings into real-world applications that enhance medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago De Compostela, A Coruña, Spain
Santiago De Compostela, , Spain
Patients applied
Trial Officials
Mario Pérez-Sayáns, PhD
Principal Investigator
University of Santiago de Compostela
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials